Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04417062 · ClinicalTrials.gov registry record · Phase 2
Olaparib With Ceralasertib in Recurrent Osteosarcoma
A Phase 2 study of Osteosarcoma and Osteosarcoma Recurrent, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
- 4
- Study locations
NCT04417062: Active Phase 2 study of Osteosarcoma and Osteosarcoma Recurrent, sponsored by Dana-Farber Cancer Institute.
NCT04417062 is a Phase 2 study of Osteosarcoma and Osteosarcoma Recurrent that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 63 participants, below the 300-participant average among 46 other Osteosarcoma trials with a reported enrollment target (79% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04417062, a Phase 2 study of Osteosarcoma and Osteosarcoma Recurrent, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study is being done in order to evaluate the effectiveness of using two drugs (olaparib and ceralasertib) to treat patients with osteosarcoma that has not responded to treatment or has come back after treatment The names of the study drugs involved in this study are: * Olaparib * Ceralasertib
Primary Outcome
An event is defined as the occurrence of relapse, disease progression as defined by RECIST 1.1, or death from any cause.
Conditions Studied
Interventions
- DRUG Olaparib
- DRUG Ceralasertib
Study Locations (4)
California
- UCSF Benioff Children's Hospital; UCSF Pediatrics Hematology Oncology - San Francisco
Massachusetts
- Dana Farber Cancer Institite - Boston
New York
- Memorial Sloan Kettering - New York
Texas
- MD Anderson - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2020-11-24 |
| Est. Completion | 2026-06-01 |
| Phase | Phase 2 |
What the registry record for NCT04417062 still lists
NCT04417062 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 300-participant average among 46 other Osteosarcoma trials with a reported enrollment target (79% lower).
The record links to 2 conditions, with Osteosarcoma appearing as the primary indexed condition, and to 2 interventions - of which Olaparib is the first listed.
NCT04417062 reports a single indexed study location in California, Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT04417062 about?
NCT04417062 is a clinical study titled "Olaparib With Ceralasertib in Recurrent Osteosarcoma". This study is being done in order to evaluate the effectiveness of using two drugs (olaparib and ceralasertib) to treat patients with osteosarcoma that has not responded to treatment or has come back after treatment The names of the study drugs involved in this study are: * Olaparib * Ceralasertib
What is the current status of trial NCT04417062?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2020-11-24. Estimated completion is 2026-06-01.
What conditions does trial NCT04417062 study?
This clinical trial studies the following conditions: Osteosarcoma, Osteosarcoma Recurrent.
What interventions are being tested in trial NCT04417062?
The interventions under investigation include: Olaparib (DRUG), Ceralasertib (DRUG).
Who is sponsoring clinical trial NCT04417062?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04417062 being conducted?
This trial has 4 study locations across California, Massachusetts, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04417062's enrollment target sits among peer trials
63 15th of 46 higher than 31 of 46 other Osteosarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Osteosarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma
RECRUITING · Phase 2
-
Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration
RECRUITING · Phase 2
-
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
ACTIVE NOT RECRUITING · Phase 2
-
Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma
ACTIVE NOT RECRUITING · Phase 2
-
SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma
ACTIVE NOT RECRUITING · Phase 2
-
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI